Section 12: Cancer Chemotherapy Chapter 55

Cumulative dose-related cardiac toxicity typically results from administration of

doxorubicin

bleomycin

vincristine

imatinib

irinotecan

doxorubicin

Vincristine inhibits mitosis of cancer cells at metaphase by

inhibiting telomerase

increasing tubulin degradation

inhibiting synthesis of tubulin

inhibiting polymerization of tubulin

stabilizing microtubules

inhibiting polymerization of tubulin

Cytarabine is converted to an active triphosphate metabolite that inhibits

DNA polymerase

adenine deaminase

dihydrofolate reductase

telomerase

thymidylate synthetase

DNA polymerase

Folinic acid can be administered to counteract the toxic effects of

fludarabine

gemcitabine

cytarabine

fluorouracil

methotrexate

methotrexate

Reactive carbonium ions that attack guanine bases of DNA and lead to crosslinking of DNA strands are formed in the body from drugs such as

cisplatin

bleomycin

doxorubicin

etoposide

cyclophosphamide

cyclophosphamide

Thymidylate synthetase is inhibited by the active metabolite of

pentostatin

fluorouracil

doxorubicin

gemcitabine

fludarabine

fluorouracil

Trastuzumab is useful in treating breast cancer because of its ability to bind

telomerase

human epidermal growth factor receptor 2

DNA transcription factors

insulin-like growth factor

calcium channel forming proteins

human epidermal growth factor receptor 2